SPDL1 and central nervous system cancer: Elevated initial sPD-L1 levels have been associated with poorer prognosis in ccRCC (57), soft tissue sarcomas (28), pancreatic adenocarcinoma (58), lung cancer (49, 59), hepatocellular carcinoma (36), and lower-grade glioma (40).